# Circadian OS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/circadian-os

- Industry: Healthcare
- Headquarters: New York, US
- Website: www.circadian-os.com/
- Latest round: Seed (Aug 12, 2025)
- Investors on record: 1

## About

Circadian OS is a New York-based HealthTech startup focused on developing innovative cancer treatment solutions through light-based therapies that enhance immunotherapy effectiveness.Circadian OS, established in 2023 in New York, US, specializes in cancer treatment solutions centered around light-based clock gene therapy. The company has completed one deal with the most recent funding round occurring on August 12, 2025. The founder has a notable history in the health technology sector, although specific past ventures are not detailed.Circadian OS specializes in innovative cancer treatment solutions that utilize light-based clock gene therapy to enhance the efficacy of immunotherapy. Their core offerings include personalized light therapy and immune clock assessment techniques, which optimize cancer treatment outcomes by aligning treatment timing with individual patients’ unique biological rhythms. The primary service involves a blood test measuring a patient's immune system rhythm, allowing precise timing of immunotherapy treatments, aimed at significantly improving patient outcomes. Circadian OS targets oncology clinics and healthcare providers, particularly in the US and Europe, focusing on advancing cancer treatment methodologies.Circadian OS generates revenue through direct partnerships with healthcare providers and oncology clinics implementing their light therapy and immune clock assessment services. The business model features a fee-for-service structure, with clinics paying for blood tests, software licensing, and ongoing support linked to personalized light therapy programs. Clients may subscribe to ongoing services, ensuring continuous integration of the therapy into their practice. Pricing for services reflects the value of optimizing immunotherapy efficacy, although specific pricing details are not disclosed. The company’s focus on non-pharmacological solutions positions it uniquely within the healthcare landscape.Circadian OS plans to leverage its recent Seed funding, raised in August 2025 from investor SOSV, to support the development of new products and expand into additional markets. The company is targeting the launch of advanced light therapy solutions designed to further enhance immunotherapy by 2026. Geographic expansion will focus on additional locations in Europe and Asia by the end of 2026, aiming to increase access to its innovative cancer treatment methodologies.

## Funding rounds

- Seed, Aug 12, 2025 — SOSV

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed